Саркопения в практике онколога
Аннотация
Саркопения - это потеря мышечной массы тела и снижение мышечных функций, обусловленные возрастными, нейрогуморальными изменениями, нарушениями питания или катаболизмом. Саркопения диагностируется у 20-70 % пациентов с распространенными новообразованиями и ассоциирована с рядом негативных эффектов. При этом данное состояние редко попадает в фокус внимания практикующих онкологов, в том числе из-за трудностей диагностики. В настоящее время «золотым стандартом)) в диагностике саркопении является определение скелетного мышечного индекса (СМИ) при компьютерной томографии. Установлено, что низкий СМИ на момент диагностики различных солидных опухолей ассоциируется с худшей общей выживаемостью. Коррекция саркопении требует мультидисциплинарного подхода: в том числе оптимального питания с поступлением достаточного количества белка, микронутриентов, а также аэробной и силовой физической нагрузки.
Об авторах
М. Ю. Кукош
ФГАОУ ВО «Российский университет дружбы народов»; ГБУЗ «Городская клиническая больница № 40» Департамента здравоохранения
Россия
Россия
М. Д. Тер-Ованесов
ФГАОУ ВО «Российский университет дружбы народов»; ГБУЗ «Городская клиническая больница № 40» Департамента здравоохранения
Россия
Россия
Список литературы
1. Лядов В. К., Буланова Е. А., Синицын В. Е. Возможности КТ при выявлении саркопении у больных с опухолевыми и воспалительными заболеваниями поджелудочной железы. Диагностическая и интервенционная радиология.2012; 6 (1). 13-18.
2. Николаев Д. В., Смирнов А. В., Бобринская И. Г., Руднев С. Г. Биоимпедансный анализ состава тела человека. М.: Наука, 2009. 392 с.
3. Руководство по клиническому питанию. Под ред. В. М. Луфта, Санкт-Петербург, 2016, 484 с.
4. Baracos VE, Relman T, Mourtzakis M, et al. Body composition in patients with nonsmall lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am. J. Clin. Nutr. 2010; 91 (4): 1133S-1137S.
5. Bischoff-Ferrari HA. Relevance of vitamin D in muscle health. Rev. Endocr. Metab. Disord. 2012; 13: 71-77.
6. Chapman I. Weight loss in older persons. Medical clinics of North America. 2011; 95 (3): 579-93.
7. Cho KM, Park H, Oh DY, et al. Skeletal muscle depletion predicts survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy.On-cotarget.2017; 8 (45): 79441-79452.
8. Choi Y, Oh DY, Kim TY. Skeletal muscle depletion predicts the prognosis of patients with advanced pancreatic cancer undergoing palliative chemotherapy. Independent of BMI. PLoS One. 2015; 10 (10): e0139749.
9. Cruz-Jentoft A. J., Baeyens J. P., Bauer J. M. et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing. 2010; 39 (4): 412-23.
10. Cushen SJ, Power DG, Ryan A.M, Nutrition assessment in oncology. Top. Clin. Nutr. 2015; 30 (1): 103-19.
11. Drummond MJ, Rasmussen BB. Leucine-enriched nutrients and the regulation of mTOR signaling and human skeletal muscle protein synthesis. Curr. Opin. Clin. Nutr. Metab. Care. 2008; 11: 222-226.
12. Ferrando AA, Sheffield-Moore M, Yeckel CW, et al. Testosterone administration to older man improves muscle function: molecular and physiological mechanisms. Am.J. Physi ol Endocrinol Metab. 2002; 282: E601-607.
13. Ferrucci L, Penninx BW, Volpano S, et al. Change in muscle strength explains accelerated decline oh physical function in older women with high IL-6 serum levels. J. Am. Geriatr, Soc. 2002; 50: 1947-1954.
14. Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: an undiagnosis condition in older adults - current consensus definition: prevalence, etiology, and consequences. International Working Group on Sarcopenia. J. Am. Med. Dir. Assoc. 2011; 12: 249-256.
15. Gonzales MC, Pastore CA, Orlandi SP, et al. Obesity paradox in cancer: new insights provided by body composition. Am J Clin Nutr. 2014; 99: 999-1005.
16. Goodpaster BH, Carlson CL, Visser M, et al. Attenuation of skeletal muscle and strength in the elderly: the health ABC study. J. Appl. Physiol. 2001; 90: 2157-2165.
17. Jansen I, Shepard DS., Katzmarzyk PT, et al. The healthcare costs of sarcopenia in the United States. J. Am. Geriatr. Soc. 2004; 52: 80-85.
18. Kovacheva EL, Hikim AP, Shen R, et al. Testosterone supplementation reverses sarcopenia in aging through regulation of myoststin, c-Jun NH2-terminal kinase, Notch, and Akt signaling pathways. Endocrinology. 2010; 151: 628-638.
19. Kubrak C, Olson K, Jha N, et al. Clinical determinants of weight loss in patients receiving radiation and chemoradiation for head and neck cancer: A prospective longitudinal view. Head Neck. 2013; 35: P. 695-703.
20. Kurk S.A, Peeters P. H.M., Dorresteijn B, et al. Evolution of skeletal muscle mass (SMM) during palliative systemic in metastatic colorectal cancer (mCRC) patients participating in the randomized phase 3 CAIRO3 study // Abstract ESMO 2016. Copenhagen, Denmark, 2016.
21. Malafarina V, Uriz-Otano F, Iniesta R, et al. Sarcopenia in the elderly: diagnosis, physiopathology and treatment. Maturitas.2012; 71: 109-114.
22. Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J. Am. Med. Dir. Assoc. 2013; 14 (8): 531-553.
23. Martin L., Birdsell L., Macdonald N., et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J. Clin. Oncol, 2013; 31 (12): 1539-1547.
24. Melton LJ, 3rd. Khosla S, Crowson CS. Epidemiology of sarcopenia. J. Am. Geriatr, Soc. 2000; 48: 625-630.
25. Messinger-Rapport В, Thomas D., Gammack H., et al. Clinical update on nursing home medicine: 2009. J. Am. Med. Dir. Association. 2009; 10: 530-53.
26. Montero-Odasso M, Duque G. Vitamin D in the aging musculoskeletal system: An authentic strength preserving hormone. Mol. Aspects. Med. 2005. 26; 203-219.
27. Morley JE, Argiles JM, Evans WJ, et al. Society for Sarcopenia, Cachexia, Wasting Disease. Nutritional recommendations for the management of sarcopenia. J. Am. Med. Dir. Association. 2010; 11: 391-396.
28. Muller MJ, Wang Z, Heymsfield SB, et al. Advances in the understanding of specific metabolic rates of major organs and tissues in humans. Curr. Opin. Clin. Nutr. Metab. Care. 2013; 16: 501-508.
29. Muscaritoli M., Anker S. D., Argiles J. et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) «cachexia-anorexia in chronic wasting diseases» and «nutrition in geriatrics». Clin. Nutr. 2010. Vol. 29, № 2. P. 154-159.
30. Philippou A, Maridaki M, Halapas A, et al. The role of the insulin-like growth factor-I (IGF-I) in skeletal muscle physiology. In Vivo. 2007; 21:45-54.
31. Prado CM, Baracos VE, McCargar LJ, et al. Body composition as an independent determinant of 5-fluoracil-based chemotherapy toxicity. Clin. Cancer.Res. 2007; 13 (1). 3264-3268.
32. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008; 29 (2). 154-159.
33. Prado CM, Antoun S, Sawyer MB. Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity. Curr. Opin. Clin. Nutr. Metab. Care. 2011; 14 (3): 250-254.
34. Rizzoli R, Reginster JY, Arnal JF, et al. Quality of life in sarcopenia and frailty. Calcif Tissue Int. Springer. 2013. DOI 10.1007/ s00223-013-9759-y.
35. Rolland Y, Onder G, Morley J, et al. Current and future pharmacological treatment of sarcopenia. Clinics in Geriatric Medicine. 2011; 27: 423-447.
36. Rosenberg IH. Sarcopenia: origins and clinical relevance. Clin. Geriatr. Med. 2011; 27. 337-339.
37. Roubenoff, Hughes VA. Sarcopenia: current concepts. J. Gerontol. A. Biol. Sci Med. Sci. 2000; 55: M716-M724.
38. Sakuma K., Yamaguchi A. Molecular mechanisms in aging and current strategies to counteract sarcopenia. Curr Aging Sci. 2010; 3: 90-101.
39. Scott D., Blizzard L., Fell J, et al. The epidemiology sarcopenia in community living older adults: what role does lifestyle play? J. Cachexia. Sarcopenia. Muscle2010; 2: 125-134.
40. Shachar S, Williams G, Muss H, Nishijima T. Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review. Eur J Cancer. 2016 Apr; 57: 58-67. doi: 10.1016/j.ejca.2015.12.030. Epub 2016 Feb 13. Review.
41. Sharma P, Zargar-Shoshtari K, Caracciolo JT, Fishman M, Poch MA, Pow-Sang J, Sexton WJ, Spiess PE. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Urol. Oncol. 2015; 33: 339.e17-23.
42. Short KR, Nair KS. The effect of age on protein metabolism. Curr. Opin. Clin. Nutr. Metab. Care. 2000; 3: 39-44.
43. Short KR, Vittone JL, Bigelow JL.et al. Age and aerobic exercise training effects on whole body and muscle protein metabolism. Am. J. Physiol. Endocrinol. Metab. 2004; 286: E 92-E 101.
44. Sinha-Hikim I, Cornford M, Gaytan H, et al. Effects of testosterone supplementation on skeletal muscle fiber hypertrophy and satellite cells in community-dwelling older man. J. Clin. Endocrinol. Metab. 2006; 91: 3024-3033.
45. Stenholm S, Harris TB, Rantanen T, et al. Sarcopenic obesity: definition, cause and consequences. Curr. Opin. Clin. Nutr. Metab. Care. 2008; 11: 693-700.
46. Tieland M, Kirks ML, van der Zwaluw N, et al. Protein supplementation increases muscle mass gain during prolonged resistance-type exercise training in frail elderly people: a randomized, double-blind, placebo-controlled trial. J. Am. Med. Dir. Association. 2012; 13 (8): 713-719.
47. Verdijk LB, Kooman R, Schaart G, et al. Satellite cell content in specifically reduced in type II skeletal muscle fibers in the elderly. Am. J. Physiol. Endocrinol. Metab. 2007; 2902: E 151-E 157.
48. Wagners AJ, Conboy IM. Cellular and molecular signatures of muscle regeneration: current concepts and controversies in adult myogenesis. Cell. 2005; 122: 659-667.
49. Waters DL Baumgartner RN, Garry PJ. Advantages of dietary, exercise-related, and therapeutic interventions to prevent and treat sarcopenia in adult patients: an update. Clin. Interv. Aging. 2010; 5:259-270.
Рецензия
Для цитирования:
Кукош М.Ю., Тер-Ованесов М.Д. Саркопения в практике онколога. Медицинский алфавит. 2018;1(15):37-43.
For citation:
Kukosh M.Yu., Ter-Ovanesov M.D. Sarcopenia in oncology practice. Medical alphabet. 2018;1(15):37-43. (In Russ.)
Просмотров:
1076
Послать статью по эл. почте 